|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.
|
30949905 |
2019 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARP1-binding protein (PARPBP/PARI/C12orf48), a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer.
|
30949905 |
2019 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
|
Pancreatic carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PARI upregulation in pancreatic cancer cells or avian DT40 cells conferred DNA repair deficiency and genomic instability.
|
23436799 |
2013 |
|
Malignant neoplasm of pancreas
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PARI upregulation in pancreatic cancer cells or avian DT40 cells conferred DNA repair deficiency and genomic instability.
|
23436799 |
2013 |
|
Pancreatic carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hence, our findings implicate C12orf48, termed PARP-1 binding protein (PARPBP), or its interaction with PARP-1 to be a potential molecular target for development of selective therapy for pancreatic cancer.
|
20931645 |
2011 |
|
Malignant neoplasm of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hence, our findings implicate C12orf48, termed PARP-1 binding protein (PARPBP), or its interaction with PARP-1 to be a potential molecular target for development of selective therapy for pancreatic cancer.
|
20931645 |
2011 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Significantly, PARI silencing compromised cancer cell proliferation in vitro, leading to cell-cycle alterations associated with S-phase delay, perturbed DNA replication, and activation of the DNA damage response pathway in the absence of DNA damage stimuli.
|
23436799 |
2013 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Significantly, PARI silencing compromised cancer cell proliferation in vitro, leading to cell-cycle alterations associated with S-phase delay, perturbed DNA replication, and activation of the DNA damage response pathway in the absence of DNA damage stimuli.
|
23436799 |
2013 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Knock-down of their human homologs (C1ORF112 and C12ORF48) in HeLa cells slowed growth, indicating that these genes of unknown function, identified by GeneFriends, may be involved in cancer.
|
23039964 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Knock-down of their human homologs (C1ORF112 and C12ORF48) in HeLa cells slowed growth, indicating that these genes of unknown function, identified by GeneFriends, may be involved in cancer.
|
23039964 |
2012 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
PARI overexpression promotes genomic instability and pancreatic tumorigenesis.
|
23436799 |
2013 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings offered a preclinical proof-of-concept for PARI as candidate therapeutic target to treat PDAC.
|
23436799 |
2013 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of C12orf48 sensitized PDAC cells to agents causing DNA damage and also enhanced DNA damage-induced G2/M arrest through reduction of PARP-1 enzymatic activities.
|
20931645 |
2011 |
|
Idiopathic Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
|
30698487 |
2020 |
|
Respiratory Distress Syndrome, Newborn
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cut-off values of FLV ≤27.2 cm<sup>3</sup> and PARI ≥0.77 predicted the subsequent development of RDS.
|
28969484 |
2019 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
|
30949905 |
2019 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analyses suggested that upregulation of PARPBP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC.
|
30949905 |
2019 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that PARI plays potential oncogenic roles and functions as a transcriptional target and effector of FOXM1 in GC development.
|
29805304 |
2018 |